|1.||Dudek, Arkadiusz Z: 4 articles (04/2011 - 06/2008)|
|2.||Zwolak, Pawel: 4 articles (04/2011 - 06/2008)|
|3.||Jasinski, Piotr: 4 articles (04/2011 - 06/2008)|
|4.||Terai, Kaoru: 4 articles (04/2011 - 06/2008)|
|5.||Borja-Cacho, Daniel: 2 articles (04/2011 - 02/2011)|
|6.||Vogel, Rachel Isaksson: 1 article (04/2011)|
|7.||Land, David: 1 article (06/2008)|
|8.||Galvez, Jorge: 1 article (06/2008)|
|9.||Welsh, Brandon: 1 article (06/2008)|
|10.||Ghandi, Lori: 1 article (06/2008)|
04/01/2011 - "The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. "
06/01/2008 - "The objective of the present study was to determine the mechanism of action of MT477 and its activity against human cancer cell lines. "
04/01/2011 - "MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling."
02/01/2011 - "Taken together, these results support the conclusion that MT477 acts as a direct PKC-α inhibitor in non-Ras mutated cancer, with maximum effectiveness when given in a continuous treatment schedule."
02/01/2011 - "H226 tumor size in mice continuously treated with intraperitoneal MT477 (1 mg/kg) was 62.1 ± 15.3% smaller than the average tumor size in control mice. "
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/01/2008 - "MT477 interfered with PKC activity as well as phosphorylation of Ras and ERK1/2 in H226 human lung carcinoma cells. "
06/01/2008 - "Two murine xenograft models of human A431 and H226 lung carcinoma were used to evaluate tumor response to intraperitoneal administration of MT477 (33 microg/kg, 100 microg/kg, and 1 mg/kg). "
06/01/2008 - "A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines."
|1.||Protein Isoforms (Isoforms)
|1.||Heterologous Transplantation (Xenotransplantation)